What is OKYO Pharma Limited's share price today?
OKYO Pharma Limited (OKYO) share price today is $1.47 as of October 23, 2026 at 1:30 AM IST. The stock touched a day high of $1.52 and a day low of $1.41.What exchange does OKYO Pharma Limited stock trade on, and under what ticker symbol?
OKYO Pharma Limited stock trades on NASDAQ under the ticker symbol OKYO.What is OKYO Pharma Limited's market capitalization?
OKYO Pharma Limited's market capitalization is $71.89M as of October 23, 2026 at 1:30 AM IST.What is OKYO Pharma Limited's price-to-earnings (P/E) ratio?
OKYO Pharma Limited's price-to-earnings (P/E) ratio is N/A as of October 22, 2026.What is OKYO Pharma Limited's price-to-book (P/B) ratio?
OKYO Pharma Limited's price-to-book (P/B) ratio is 5.53 as of October 22, 2026.Can Indian investors buy OKYO Pharma Limited shares?
Yes, You can buy OKYO Pharma Limited shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in OKYO Pharma Limited shares from India?
Indian investors can buy OKYO Pharma Limited shares in three steps: 1. Search OKYO Pharma Limited on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from OKYO Pharma Limited shares for Indian investors?
Since OKYO Pharma Limited trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in OKYO Pharma Limited shares via Tickertape?
Indian investors can start investing in OKYO Pharma Limited (OKYO) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 6.7796 shares at the current price of $1.47.
$
₹
$1.474.22% (-0.06)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
—
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
5.53
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$-0.24
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
—
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
0%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 3 analysts reports
Buy3 analysts
Hold0 analyst
Sell0 analyst
Price Upside
+466.89%
Earnings Growth
-100%
Rev. Growth
—
Company Profile
Company Profile
ABBV
P/E Ratio
81.66
81.66
1Y Return
24.54%
24.54%
Buy Reco %
80.00
80.00
AMGN
P/E Ratio
27.26
27.26
1Y Return
49.15%
49.15%
Buy Reco %
35.29
35.29
P/E Ratio
—
—
1Y Return
29.41%
29.41%
Buy Reco %
78.57
78.57
P/E Ratio
29.80
29.80
1Y Return
25.49%
25.49%
Buy Reco %
81.25
81.25
MRNA
P/E Ratio
—
—
1Y Return
654.67%
654.67%
Buy Reco %
21.73
21.73
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$1.47Baseline
Analyst Target - 1 year
Target$8.33+466.89%
All values in $
2026
Current$1.47Baseline
Analyst Target - 1 year
Target$8.33+466.89%
All values in $
Earnings Per Share Forecast
Earnings Per Share Forecast
2026
Current$-0.06Baseline
Forecast for Mar 2027
High$-0.12-100%
Average$-0.12-100%
Low$-0.12-100%
All values in $
2026
Current$-0.06Baseline
Forecast for Mar 2027
High$-0.12-100%
Average$-0.12-100%
Low$-0.12-100%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | - | -0 |
| Net Income | -0 | -0 | -0 | -2.67 | -0 | -2.02 | -2.02 | -2.58 | - | -6.36 |
| Net Profit Margin | - | - | - | - | - | - | - | - | - | - |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| OKYO Pharma Limited | - | 5.53 | - |
| AbbVie Inc | 81.66 | 50.45 | 0.54 |
| Amgen Inc | 27.26 | 18.78 | 2.45 |
Price Comparison
Price Comparison
Compare OKYO with any stock or ETFCompare OKYO with any stock or ETF
Comparing from
OKYO
ABBV
AMGN
The 12-month consensus target implies 466.89% growth, versus a trailing 3-year CAGR of -3.39%.